Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Harshit Gupta headshot

McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?

by Harshit Gupta

McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

by Zacks Equity Research

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.

Integer Holdings (ITGR) Gains 21.9% YTD: What's Driving the Stock?

by Zacks Equity Research

Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.

DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

by Zacks Equity Research

DexCom (DXCM) announces that Quebec residents aged two years and older living with type 1 diabetes may now be eligible to receive coverage for Dexcom G7.

The Joint (JYNT) Forays Into San Francisco Chiropractic Market

by Zacks Equity Research

This year, The Joint (JYNT) intends to open 60-70 new franchised clinics compared with 104 opened last year.

Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA

by Zacks Equity Research

Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.

Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.

Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia

by Zacks Equity Research

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI

by Zacks Equity Research

Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.

Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised

by Zacks Equity Research

Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.

Philips (PHG) Extends Isala Partnership, Boosts Customer Base

by Zacks Equity Research

Philips (PHG) extends its partnership Isala hospital to optimize the latter's healthcare processes, expanding its customer base.

Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales

by Zacks Equity Research

Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

by Zacks Equity Research

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Should Value Investors Buy Quest Diagnostics (DGX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on cost efficiency programs raises optimism about the stock.

Harshit Gupta headshot

Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments

by Harshit Gupta

Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

by Zacks Equity Research

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare

by Zacks Equity Research

Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

by Zacks Equity Research

A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

by Zacks Equity Research

Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.

Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge

by Zacks Equity Research

Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.

Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure

by Zacks Equity Research

Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

by Zacks Equity Research

Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.